top of page

FDA Approves Talzenna Plus Xtandi in Hormone-Sensitive Prostate Cancer

10/26/26, 3:00 PM

The FDA approved Talzenna plus Xtandi for adults with HRR-mutated metastatic prostate cancer that has not been treated with, or is still responding to, androgen pathway drugs.

CONTACT US

Our office is open Monday through Thursday, excluding holidays, from 10 a.m. to 2 p.m. 

 

If you need assistance on weekends, please call
(505) 254-7784 and your call will be forwarded to a PCSANM volunteer. We’re here to answer your questions.

2533 Virginia St  NE   Suite C Albuquerque, NM 87110   

Phone: (505) 254-7784   

Toll Free: (800) 278-7678    

  • Facebook

Disclaimer

​

PCSANM provides education, information, and support, not medical advice. We are not medical professionals. Please consult your physician for any medical concerns.

Prostate Cancer Support Association of New Mexico

© 2025 Prostate Cancer Support Association of New Mexico

bottom of page